CD28 Regulation of Alternative Splicing Changes in Human T cells
CD28 对人类 T 细胞选择性剪接变化的调节
基本信息
- 批准号:10543406
- 负责人:
- 金额:$ 1.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2023-02-28
- 项目状态:已结题
- 来源:
- 关键词:Alternative SplicingAntibodiesAntigen PresentationAntigen-Presenting CellsApoptoticCASP9 geneCD28 geneCD3 AntigensCD4 Positive T LymphocytesCell DeathCell SurvivalCell physiologyCellsComputer softwareCultured CellsDataEventExclusionExhibitsExonsFutureGene ExpressionGenesGeneticGoalsHarvestHigh-Throughput Nucleotide SequencingHumanImmune systemInfectionKnowledgeMessenger RNAMonoclonal Antibody HuM291PTPRC genePeptidesPhenotypePhysiologicalProcessProductionProliferatingProtein IsoformsProtein Tyrosine PhosphataseProteinsRNARNA ProcessingRNA SplicingRNA-Binding ProteinsRegulationReverse Transcriptase Polymerase Chain ReactionRoleSamplingSignal InductionSignal PathwaySignal TransductionSpliced GenesStimulusT-Cell ActivationT-Cell ReceptorT-LymphocyteTestingTitrationsTranscriptWorkcytokineexon skippingnovelpathogenreceptorresponsetooltranscriptome sequencing
项目摘要
Project Summary
Alternative splicing consists of exons that are selectively included or excluded from the mature mRNA
transcript. In fact, most protein encoding genes, approximately 95%, contain an alternative exon. Previous
studies recognized that a subset of alternative spliced genes, 10-15%, undergo changes in isoform abundance
upon activation of primary human CD4+ T cells. A well-characterized example of signal-induced alternative
splicing changes includes a tyrosine phosphatase receptor, CD45, where the increased abundance of the
shorter RNA isoform is correlated with an increased activation threshold from future stimuli. Regulatory
mechanisms including the role of signaling pathways and RNA binding proteins influencing splicing changes
have been characterized by our lab and others. However, the field lacks general knowledge of the role and
mechanism of differential T cell stimuli to regulate global splicing changes.
Previous studies investigated signal-induced alternative splicing changes with T cells activated in the
presence of anti-CD3 and anti-CD28 stimuli. CD3 is a component of the T cell receptor (TCR), which is
responsible for recognizing peptides presented by antigen presenting cells in the context of an infection. CD28
is a costimulatory receptor that enhances many signaling events downstream of the TCR. We ask if global
alternative splicing changes are differentially influenced by the presence of CD28 costimulation in primary
human CD4+ T cells. Therefore, I acquired primary CD4+ CD45RO- T cells from three human donors and
cultured the cells in the following conditions: media alone, anti-CD28 antibody, anti-CD3 antibody, or anti-
CD3/CD28 together. I harvested RNA for high-throughput sequencing analysis and discovered a subset of
alternative splicing events that are influenced by the presence CD28 costimulation compared to splicing events
regulated by CD3 stimulation alone. One of these splicing events includes a multi-exon skipping event within
Casapse-9 transcript that has not been characterized in CD4+ T cells. We hypothesize that the multi-exon
skipping event is regulating T cell survival upon stimulation. In our proposal, we plan to elucidate mechanisms
of splicing changes regulated by CD28 costimulation and the functional consequences of such events, such as
the multi-exon skipping event in Caspase-9 and impact on T cell survival. Overall, this work will be the stepping
stone into knowing how global alternative splicing events are regulated and the impact on cellular functions.
项目摘要
替代剪接由选择性包括或排除在成熟mRNA中的外显子组成
成绩单。实际上,大多数编码基因的蛋白质(约95%)都包含替代外显子。以前的
研究认识到,替代剪接基因的子集(10-15%)发生了同工型丰度的变化
激活原代人CD4+ T细胞后。信号诱导的替代方案的典型示例
剪接变化包括酪氨酸磷酸酶受体CD45,其中增加的丰度
较短的RNA同工型与未来刺激的激活阈值相关。监管
机制,包括信号通路的作用和影响剪接变化的RNA结合蛋白
以我们的实验室和其他人为特征。但是,该领域缺乏对角色和
差分T细胞刺激的机制调节全局剪接变化。
先前的研究研究了信号引起的替代剪接变化,随着T细胞的激活
抗CD3和抗CD28刺激的存在。 CD3是T细胞受体(TCR)的组成部分,
负责在感染的背景下识别由抗原呈递细胞呈现的肽。 CD28
是一种共同刺激受体,可增强TCR下游的许多信号事件。我们问全球是否
替代剪接变化受主要的CD28共刺激存在差异的影响
人CD4+ T细胞。因此,我从三个人类捐赠者那里获得了主要的CD4+ CD45ro-T细胞,
在以下情况下培养细胞:单独培养基,抗CD28抗体,抗CD3抗体或抗体
CD3/CD28一起。我收集了RNA进行高通量测序分析,并发现了一个子集
与剪接事件相比,受到存在CD28共刺激影响的替代剪接事件
仅由CD3刺激调节。这些拼接事件之一包括在
Casapse-9在CD4+ T细胞中尚未表征的转录本。我们假设多述
跳过事件是调节刺激后的T细胞存活。在我们的建议中,我们计划阐明机制
由CD28共刺激调节的剪接变化和此类事件的功能后果,例如
caspase-9中的多外观跳过事件以及对T细胞存活的影响。总的来说,这项工作将是阶梯
知道如何调节全球替代剪接事件以及对细胞功能的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Davia Blake其他文献
Davia Blake的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Davia Blake', 18)}}的其他基金
CD28 Regulation of Alternative Splicing Changes in Human T cells
CD28 对人类 T 细胞选择性剪接变化的调节
- 批准号:
10252785 - 财政年份:2021
- 资助金额:
$ 1.01万 - 项目类别:
相似国自然基金
人源化小鼠筛选猴痘抗体及机制研究
- 批准号:82373778
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
抗HTNV抗体mRNA修饰MSC在肾综合征出血热治疗中的作用研究
- 批准号:82302487
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
人和小鼠中新冠病毒RBD的免疫原性表位及其互作抗体的表征和结构组学规律的比较研究
- 批准号:32371262
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向肿瘤内T细胞的双特异性抗体治疗策略研究
- 批准号:82371845
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
靶向DLL3和γδ T细胞的双特异抗体对小细胞肺癌的免疫治疗活性研究
- 批准号:32300783
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Mapping tumor specific immunopeptidome for antibody-based targeted therapy
绘制肿瘤特异性免疫肽组用于基于抗体的靶向治疗
- 批准号:
10604941 - 财政年份:2023
- 资助金额:
$ 1.01万 - 项目类别:
HLA-Releasing Metalloproteinase in Allograft Rejection
同种异体移植排斥中 HLA 释放金属蛋白酶
- 批准号:
7923507 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
SLAM Gene Family Controlled Pathways to SLE
SLAM 基因家族控制 SLE 通路
- 批准号:
8339525 - 财政年份:2006
- 资助金额:
$ 1.01万 - 项目类别:
SLAM Gene Family Controlled Pathways to SLE
SLAM 基因家族控制 SLE 通路
- 批准号:
8513250 - 财政年份:2006
- 资助金额:
$ 1.01万 - 项目类别:
SLAM Gene Family Controlled Pathways to SLE
SLAM 基因家族控制 SLE 通路
- 批准号:
8707309 - 财政年份:2006
- 资助金额:
$ 1.01万 - 项目类别: